Compound library
Understand what people are taking.
Browse medicines, supplements, herbs, and health foods. Each profile brings community reports and linked research into one clear view.
Browse medicines, supplements, herbs, and health foods. Each profile brings community reports and linked research into one clear view.
Compound made by gut bacteria from ellagitannins in pomegranate and walnuts, and sold ready-made (for example Mitopure) because not everyone's gut bacteria produce it. Trials show it changes mitochondrial and inflammation markers in people; effects on muscle strength and endurance are mixed, and the two main trials in middle-aged and older adults missed their primary endpoints.
5 of 9 results reported a benefit, from 2 published studies.
2 randomised trials, 66 people
These are the figures the studies reported, not a prediction for any one person. Where several studies measured the same thing in the same unit, we show a simple average and say so. Every individual result is listed below.
See every resultSustained physical performance — cardiovascular capacity, stamina, and oxygen utilisation during prolonged exercise.
Also known as: UA, Mitopure
Every published result for this pair, extracted and audited.
These charts group published studies by what they reported and how they were run — green marks studies that reported a benefit for this pairing. Tiers run from pooled analyses of many trials (strongest) to one-off observational reports.
Direction of reported outcomes for Urolithin A in endurance.
Study designs behind these findings.
Hand-selected PubMed studies, linked to the originals.
Be the first to share what you noticed with Urolithin A for endurance. Why counts start empty.
Every measured outcome, one row per finding - numbers exactly as reported.
| Study | Design | n | Duration | Outcome measured | Reported result | Direction |
|---|---|---|---|---|---|---|
| PMID 40839339 2025 | Randomised trial | 42 | 4 weeks | Creatine kinase (CK) total area under the curve | reported qualitatively (p < 0.0001) | Benefit |
| PMID 40839339 2025 | Randomised trial | 42 | 4 weeks | Ratings of perceived exertion (RPE) | reported qualitatively (p = 0.02) | Benefit |
| PMID 40839339 2025 | Randomised trial | 42 | 4 weeks | Running performance (3000 m time trial) | reported qualitatively (p = 0.116; p = 0.771) | No benefit |
| PMID 35050355 2022 | Randomised trial | 66 | 4 months | 6-minute walk distance | 60.8 (67.2) m | No benefit |
| PMID 35050355 2022 | Randomised trial | 66 | 4 months | Maximal ATP production in first dorsal interosseus (FDI) muscle | 0.07 (0.23) mM/s | No benefit |
| PMID 35050355 2022 | Randomised trial | 66 | 4 months | Maximal ATP production in tibialis anterior (TA) muscle | -0.03 (0.10) mM/s | No benefit |
| PMID 35050355 2022 | Randomised trial | 66 | 4 months | Muscle endurance in first dorsal interosseus (FDI) muscle | 95.3 [115.5] | Benefit |
| PMID 35050355 2022 | Randomised trial | 66 | 4 months | Muscle endurance in tibialis anterior (TA) muscle | 41.4 [65.5] | Benefit |
| PMID 35050355 2022 | Randomised trial | 66 | 4 months | Plasma levels of acylcarnitines, ceramides, and C-reactive protein | reported qualitatively | Benefit |